Tirzepatide and retatrutide are both incretin-based peptides studied in metabolic research. Tirzepatide is an approved dual agonist with a large body of clinical data behind it. Retatrutide is newer and still investigational; as of mid-2026 it has reported its first pivotal Phase 3 readout but remains unapproved. What follows is drawn from the published literature and trial readouts on each. It is not medical advice, and neither compound should be used outside a licensed clinical or research context.
How Each Compound Works
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It's a single synthetic peptide engineered to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor at once. Both receptors play a part in insulin secretion, appetite signaling, and gastric emptying. The FDA approved tirzepatide as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023, making it the first approved agent in the dual-agonist class.
Retatrutide is described in the literature as a triple GIP/GLP-1/glucagon receptor agonist. It adds agonism at the glucagon receptor on top of the dual-receptor profile it shares with tirzepatide. In preclinical models, glucagon receptor activation is tied to increased energy expenditure and hepatic fat mobilization. Retatrutide is investigational and has not received regulatory approval. Material sold under its name outside a clinical trial is research use only, not approved for human consumption.
What Trial Readouts Have Reported
Clinical data for tirzepatide comes from the SURPASS series of trials in type 2 diabetes and the SURMOUNT series in obesity. Across those readouts, researchers reported reductions in body weight and improvements in glycemic markers. Publications described these as among the largest seen for an approved agent in those indications at the time. SURMOUNT-1 reported mean weight reductions of up to roughly 22.5% at the highest dose. The trials ran at multiple doses and compared against placebo and active comparators including semaglutide.
Retatrutide's Phase 2 obesity trial was published in The New England Journal of Medicine in June 2023 (NCT04881706). In that randomized, placebo-controlled study of 338 adults, Eli Lilly (which develops both compounds) reported a mean weight reduction of 24.2% at the 12-mg dose after 48 weeks, against 2.1% for placebo, with favorable signals on liver fat and lipid markers. On May 21, 2026, Lilly announced positive topline results from TRIUMPH-1, the first pivotal Phase 3 obesity trial. It reported weight reductions of roughly 25–28% on average across the higher doses at 80 weeks (about 2,339 participants), with a subset continuing to a 104-week extension. Other TRIUMPH Phase 3 trials in obesity, obstructive sleep apnea, knee osteoarthritis, and type 2 diabetes were ongoing as of that announcement. The broader Phase 3 program had not fully read out and the compound was not yet approved, so the complete benefit-risk profile, including long-term safety data, was not yet established in the public record.
Side-by-Side Summary
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Regulatory status | FDA-approved (US) | Investigational (first Phase 3 readout May 2026; not approved) |
| Clinical data volume | Large (Phase 3 complete, post-marketing ongoing) | Growing (Phase 2 published; first Phase 3 readout reported) |
| Weight outcomes reported | Up to ~22.5% in SURMOUNT-1 | ~24.2% at 12 mg / 48 wks (Phase 2); ~25–28% at higher doses / 80 wks (TRIUMPH-1 topline) |
| Glucagon agonism | No | Yes — associated in models with increased energy expenditure |
| Approval for human use | Yes (prescription, specific indications) | No — research use only |
Key Uncertainties
A third receptor target does not automatically make for a better therapeutic profile. Glucagon receptor agonism carries a theoretical risk of glycemic variability. Whether the triple-agonist mechanism translates into durable outcomes across the full Phase 3 program is not yet established by completed, peer-reviewed data. Tirzepatide has the advantage of a larger safety dataset built up across approved use. The remaining TRIUMPH Phase 3 readouts and full peer-reviewed publications will show whether the early signals hold and what the tolerability profile looks like over longer durations.
No direct head-to-head randomized results between the two compounds have been published as of this article. A Phase 3 trial comparing retatrutide and tirzepatide directly in adults with obesity is registered on ClinicalTrials.gov (NCT06662383), with completion expected in late 2026. Read comparisons across separate trial programs with caution, since study design, populations, and dose-escalation schedules differ.
Sources
- NEJM — Triple–Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2)
- Eli Lilly — TRIUMPH-1 Phase 3 retatrutide topline results (May 2026)
- ClinicalTrials.gov — Retatrutide vs Tirzepatide in adults with obesity (NCT06662383)
- Drugs.com — Zepbound (tirzepatide) FDA approval history
- FDA — drug approval information
- Finnrick — research peptide compound reference and sourcing index